ONE OBJECTIVE: VALIDATING OUR RIFT VALLEY FEVER VACCINE CANDIDATE
LARISSA will manufacture and validate a vaccine for the prevention of Rift Valley fever in humans. The project encompasses vaccine manufacturing, preclinical research, and a Phase 1 study to assess the safety, tolerability, and immunogenicity of a single-dose of the vaccine.
To produce this vaccine candidate, researchers at Wageningen Bioveterinary Research (WBVR) have altered the genome of the Rift Valley fever virus in a way that makes it harmless for both animals and humans. This “attenuated” virus will be used as a vaccine to generate a lasting immune response against the disease.